Immunizing against Anogenital Cancer: HPV Vaccines

Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine

(2015) H. Seitz et al.   Cancer Prevention Research

Development of a highly thermostable, adjuvanted human papillomavirus vaccine

(2015) Kimberly J. Hassett et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Prophylactic papillomavirus vaccines

(2014) Lis Ribeiro-Müller et al.   CLINICS IN DERMATOLOGY

Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women

(2013) Simon R. M. Dobson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States

(2012) Harrell W. Chesson et al.   VACCINE

Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: Immunological problems and future directions

(2011) Jiezhong Chen et al.   CELLULAR IMMUNOLOGY

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

(2011) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Vaccines to Prevent Infections by Oncoviruses

(2010) John T. Schiller et al.   Annual Review of Microbiology

Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines

(2009) Subhashini Jagu et al.   JNCI-Journal of the National Cancer Institute